Ken Griffin Revance Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 281,200 shares of RVNC stock, worth $722,684. This represents 0.0% of its overall portfolio holdings.

Number of Shares

281,200

Previous 72,100 290.01%

Holding current value

$722,684

Previous $185,000 290.27%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	N/A	91,118 New	91,118 $234,000
Q2 2024 Aug 14, 2024	BUY	$2.34 - $4.73 $464,176 - $938,271	198,366 Added 391.54%	249,029 $640,000
Q1 2024 May 15, 2024	SELL	$4.65 - $9.31 $1.41 Million - $2.82 Million	-302,999 Reduced 85.67%	50,663 $249,000
Q4 2023 Feb 14, 2024	BUY	$5.81 - $11.2 $1.32 Million - $2.55 Million	227,280 Added 179.84%	353,662 $3.11 Million
Q3 2023 Nov 14, 2023	BUY	$11.47 - $25.07 $769,442 - $1.68 Million	67,083 Added 113.13%	126,382 $1.45 Million
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $1.13 Million - $1.72 Million	45,849 Added 340.88%	59,299 $1.5 Million
Q1 2023 May 15, 2023	SELL	$18.36 - $35.27 $2.76 Million - $5.31 Million	-150,474 Reduced 91.79%	13,450 $433,000
Q4 2022 Feb 14, 2023	SELL	$18.32 - $30.66 $3.04 Million - $5.09 Million	-166,045 Reduced 50.32%	163,924 $3.03 Million
Q3 2022 Nov 14, 2022	SELL	$14.33 - $28.47 $6.3 Million - $12.5 Million	-439,615 Reduced 57.12%	329,969 $8.91 Million
Q2 2022 Aug 15, 2022	BUY	$11.52 - $20.4 $1.2 Million - $2.13 Million	104,391 Added 15.69%	769,584 $10.6 Million
Q1 2022 May 16, 2022	BUY	$12.36 - $20.31 $7.5 Million - $12.3 Million	606,635 Added 1035.96%	665,193 $13 Million
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $110,719 - $247,652	8,886 Added 17.89%	58,558 $955,000
Q3 2021 Nov 15, 2021	SELL	$25.78 - $33.21 $2.23 Million - $2.87 Million	-86,548 Reduced 63.54%	49,672 $1.38 Million
Q2 2021 Aug 16, 2021	BUY	$26.8 - $31.84 $3.33 Million - $3.96 Million	124,437 Added 1056.07%	136,220 $4.04 Million
Q4 2020 Feb 16, 2021	SELL	$23.41 - $28.34 $5.78 Million - $7 Million	-246,899 Reduced 95.44%	11,783 $334,000
Q3 2020 Nov 16, 2020	BUY	$23.23 - $34.3 $5.65 Million - $8.35 Million	243,335 Added 1585.55%	258,682 $6.5 Million
Q2 2020 Aug 14, 2020	SELL	$12.6 - $26.55 $5,443 - $11,469	-432 Reduced 2.74%	15,347 $375,000
Q1 2020 May 15, 2020	SELL	$12.46 - $27.81 $177,642 - $396,487	-14,257 Reduced 47.47%	15,779 $234,000
Q4 2019 Feb 14, 2020	SELL	$11.66 - $20.15 $1.55 Million - $2.67 Million	-132,716 Reduced 81.54%	30,036 $487,000
Q3 2019 Nov 14, 2019	BUY	$10.22 - $14.5 $198,564 - $281,720	19,429 Added 13.56%	162,752 $2.12 Million
Q2 2019 Aug 14, 2019	SELL	$10.67 - $15.49 $673,575 - $977,852	-63,128 Reduced 30.58%	143,323 $1.86 Million
Q1 2019 May 15, 2019	BUY	$15.4 - $20.39 $3 Million - $3.97 Million	194,862 Added 1681.44%	206,451 $0
Q4 2018 Feb 14, 2019	SELL	$18.06 - $24.96 $1.9 Million - $2.62 Million	-105,080 Reduced 90.07%	11,589 $233,000
Q3 2018 Nov 13, 2018	SELL	$23.55 - $30.1 $1.13 Million - $1.45 Million	-48,028 Reduced 29.16%	116,669 $0
Q2 2018 Aug 10, 2018	BUY	$27.45 - $33.35 $2.2 Million - $2.67 Million	80,086 Added 94.65%	164,697 $0
Q1 2018 May 11, 2018	BUY	$29.15 - $37.4 $1.43 Million - $1.84 Million	49,157 Added 138.65%	84,611 $2.61 Million
Q4 2017 Feb 09, 2018	BUY	$24.55 - $36.3 $870,395 - $1.29 Million	35,454	35,454 $1.27 Million

Others Institutions Holding RVNC

# of Institutions

208

Shares Held

80.9M

Call Options Held

2.26M

Put Options Held

5.48M

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account